Tango Therapeutics, Inc.
TNGX
株式のランク
#4543
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
株価
$27.18
最終同期: 2026-07-31
時価総額
$3.38B
変化（1日）
-1.41%
変化（1年）
202.34%
国
US
取引 Tango Therapeutics, Inc. (TNGX)
カテゴリー
Healthcare
Tango Therapeutics, Inc.（TNGX）の収益
Jun 2026 時点の収益 TTM: $53.81M
Tango Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は $53.81M です。2023 年には $36.53M の収益があり、これは 2022 年の $24.86M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Tango Therapeutics, Inc. の収益履歴（2019 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $53.81M | 27.91% |
| 2024 | $42.07M | 15.17% |
| 2023 | $36.53M | 46.93% |
| 2022 | $24.86M | -32.89% |
| 2021 | $37.04M | 383.83% |
| 2020 | $7.66M | -68.94% |
| 2019 | $24.65M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 23,360.44% |
US
|
|
| $2.23B | 4,040.42% |
US
|
|
| $15.74B | 29,158.57% |
AU
|
|
| $6.02B | 11,089.70% |
NL
|
|
| - | - |
CH
|
